Integrated in Silico MS-based Phosphoproteomics and Network Enrichment Analysis of RASopathy Proteins

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2021 Jul 7

PMID 34229750

Citations 3

Authors

Javier-Fernando Montero-Bullon

Oscar Gonzalez-Velasco

Maria Isidoro-Garcia

Jesus Lacal

Affiliations

Soon will be listed here.

Abstract

Background: RASopathies are a group of syndromes showing clinical overlap caused by mutations in genes affecting the RAS-MAPK pathway. Consequent disruption on cellular signaling leads and is driven by phosphoproteome remodeling. However, we still lack a comprehensive picture of the different key players and altered downstream effectors.

Methods: An in silico interactome of RASopathy proteins was generated using pathway enrichment analysis/STRING tool, including identification of main hub proteins. We also integrated phosphoproteomic and immunoblotting studies using previous published information on RASopathy proteins and their neighbors in the context of RASopathy syndromes. Data from Phosphosite database ( www.phosphosite.org ) was collected in order to obtain the potential phosphosites subjected to regulation in the 27 causative RASopathy proteins. We compiled a dataset of dysregulated phosphosites in RASopathies, searched for commonalities between syndromes in harmonized data, and analyzed the role of phosphorylation in the syndromes by the identification of key players between the causative RASopathy proteins and the associated interactome.

Results: In this study, we provide a curated data set of 27 causative RASopathy genes, identify up to 511 protein-protein associations using pathway enrichment analysis/STRING tool, and identify 12 nodes as main hub proteins. We found that a large group of proteins contain tyrosine residues and their biological processes include but are not limited to the nervous system. Harmonizing published RASopathy phosphoproteomic and immunoblotting studies we identified a total of 147 phosphosites with increased phosphorylation, whereas 47 have reduced phosphorylation. The PKB signaling pathway is the most represented among the dysregulated phosphoproteins within the RASopathy proteins and their neighbors, followed by phosphoproteins implicated in the regulation of cell proliferation and the MAPK pathway.

Conclusions: This work illustrates the complex network underlying the RASopathies and the potential of phosphoproteomics for dissecting the molecular mechanisms in these syndromes. A combined study of associated genes, their interactome and phosphorylation events in RASopathies, elucidates key players and mechanisms to direct future research, diagnosis and therapeutic windows.

Citing Articles

Biomarker Landscape in RASopathies.

Ferrito N, Baez-Flores J, Rodriguez-Martin M, Sastre-Rodriguez J, Coppola A, Isidoro-Garcia M Int J Mol Sci. 2024; 25(16).

PMID: 39201250 PMC: 11354534. DOI: 10.3390/ijms25168563.

Non-Mammalian Models for Understanding Neurological Defects in RASopathies.

Rodriguez-Martin M, Baez-Flores J, Ribes V, Isidoro-Garcia M, Lacal J, Prieto-Matos P Biomedicines. 2024; 12(4).

PMID: 38672195 PMC: 11048513. DOI: 10.3390/biomedicines12040841.

Changes of RAS Pathway Phosphorylation in Lymphoblastoid Cell Lines from Noonan Syndrome Patients Carrying Hypomorphic Variants in Two NS Genes.

Tritto V, Capitanio D, Gelfi C, Riva P Int J Mol Sci. 2023; 24(4).

PMID: 36835447 PMC: 9959625. DOI: 10.3390/ijms24044035.

References

Tidyman W, Rauen K . Expansion of the RASopathies. Curr Genet Med Rep. 2016; 4(3):57-64. PMC: 5142630. DOI: 10.1007/s40142-016-0100-7. View

Agazie Y, Movilla N, Ischenko I, Hayman M . The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 2003; 22(44):6909-18. DOI: 10.1038/sj.onc.1206798. View

Borkhardt A, Bojesen S, Haas O, Fuchs U, Bartelheimer D, Loncarevic I . The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci U S A. 2000; 97(16):9168-73. PMC: 16840. DOI: 10.1073/pnas.150079597. View

Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N . Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010; 31(3):284-94. DOI: 10.1002/humu.21187. View

Cordeddu V, Di Schiavi E, Pennacchio L, Maayan A, Sarkozy A, Fodale V . Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009; 41(9):1022-6. PMC: 2765465. DOI: 10.1038/ng.425. View

Chen J, Zhu X, Zhao T, Wang J, Yang Y, Tan Z . Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11. Mol Cytogenet. 2014; 7:28. PMC: 4031927. DOI: 10.1186/1755-8166-7-28. View

Marin T, Keith K, Davies B, Conner D, Guha P, Kalaitzidis D . Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011; 121(3):1026-43. PMC: 3049377. DOI: 10.1172/JCI44972. View

Hart K, Robertson S, Donoghue D . Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell. 2001; 12(4):931-42. PMC: 32277. DOI: 10.1091/mbc.12.4.931. View

Koenighofer M, Hung C, McCauley J, Dallman J, Back E, Mihalek I . Mutations in RIT1 cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype. Clin Genet. 2015; 89(3):359-66. PMC: 4760689. DOI: 10.1111/cge.12608. View

10.

Pevec U, Rozman N, Gorsek B, Kunej T . RASopathies: Presentation at the Genome, Interactome, and Phenome Levels. Mol Syndromol. 2016; 7(2):72-9. PMC: 4906431. DOI: 10.1159/000445733. View

11.

Cirstea I, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D . A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2009; 42(1):27-9. PMC: 3118669. DOI: 10.1038/ng.497. View

12.

Croonen E, Nillesen W, Schrander C, Jongmans M, Scheffer H, Noordam C . Noonan syndrome: comparing mutation-positive with mutation-negative dutch patients. Mol Syndromol. 2013; 4(5):227-34. PMC: 3711482. DOI: 10.1159/000350686. View

13.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong X . Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012; 287(33):28087-98. PMC: 3431627. DOI: 10.1074/jbc.M112.377218. View

14.

Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F . HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004; 64(8):2649-51. DOI: 10.1158/0008-5472.can-03-4026. View

15.

Kang S, Dong S, Gu T, Guo A, Cohen M, Lonial S . FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007; 12(3):201-14. PMC: 2424114. DOI: 10.1016/j.ccr.2007.08.003. View

16.

Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T . Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007; 44(12):763-71. PMC: 2652823. DOI: 10.1136/jmg.2007.050450. View

17.

Sewduth R, Pandolfi S, Steklov M, Sheryazdanova A, Zhao P, Criem N . The Noonan Syndrome Gene Controls Cardiovascular Function by Regulating Vesicular Trafficking. Circ Res. 2020; 126(10):1379-1393. PMC: 8575076. DOI: 10.1161/CIRCRESAHA.119.315730. View

18.

Pannone L, Bocchinfuso G, Flex E, Rossi C, Baldassarre G, Lissewski C . Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome. Hum Mutat. 2017; 38(4):451-459. DOI: 10.1002/humu.23175. View

19.

Yamamoto G, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S . Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015; 52(6):413-21. DOI: 10.1136/jmedgenet-2015-103018. View

20.

Krejci P . The paradox of FGFR3 signaling in skeletal dysplasia: why chondrocytes growth arrest while other cells over proliferate. Mutat Res Rev Mutat Res. 2013; 759:40-8. DOI: 10.1016/j.mrrev.2013.11.001. View